SCR-4026 disrupts nNOS-PSD-95 association with an IC50 of 6.3 μM in vitro.
SCR-4026 shows dose-dependent neuroprotective activities in NMDA and OGD model.
Treatment with SCR-4026 results in decreased nNOS-PSD-95 association in NMDA model.
SCR-4026 promotes neural precursor cells to differentiate into neurons-like cells.
Treatment with SCR-4026 alleviates brain injury in rat MCAO model.